Journal of the American Society of Hypertension
Volume 3, Issue 1 , Pages 3-8 , January 2009

Effects of angiotensin II receptor blockade on glucose metabolism via AMP-activated protein kinase in insulin-resistant hypertensive rats

Received 12 May 2008 ,Accepted 8 August 2008.

References 

  1. Roche HM, Phillips C, Gibney MJ. The metabolic syndrome: the crossroads of diet and genetics. Proc Nutr Soc. 2005;64:371–377
  2. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes. 2005;54:3252–3257
  3. Yu M, Stepto NK, Chibalin AV, Fryer LG, Carling D, Krook A, et al. Metabolic and mitogenic signal transduction in human skeletal muscle after intense cycling exercise. J Physiology. 2003;546:327–335
  4. Hardie DG. AMP-activated protein kinase: a key system mediating metabolic responses to exercise. Med Sci Sports Exerc. 2004;36:28–34
  5. Iglesias MA, Furler SM, Cooney GJ, Kraegen EW, Ye JM. AMP-activated protein kinase activation by AICAR increases both muscle fatty acid and glucose uptake in white muscle of insulin-resistant rats in vivo. Diabetes. 2004;53:1649–1654
  6. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels (A potential role for serine phosphorylation in insulin/angiotensin II crosstalk). J Clin Invest. 1997;100:2158–2169
  7. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci U S A. 1996;29:12490–12495
  8. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension. 2001;38:884–890
  9. Higashiura K, Ura N, Takada T, Li Y, Torii T, Togashi N, et al. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens. 2000;13:290–297
  10. Kiens B. Skeletal muscle lipid metabolism in exercise and insulin resistance. Physiol Rev. 2006;86:205–243
  11. He J, Watkins S, Kelley DE. Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes. 2001;50:817–823
  12. Furuhashi M, Ura N, Murakami H, Hyakukoku M, Yamaguchi K, Higashiura K, et al. Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. J Endocrinol. 2002;174:321–329
  13. Russell RR, Bergeron R, Shulman GI, Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol. 1999;277:H643–H649
  14. Kamide K, Rakugi H, Higaki J, Okamura A, Nagai M, Moriguchi K, et al. The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. Am J Hypertens. 2002;15:66–71
  15. Shinshi Y, Higashiura K, Yoshida D, Togashi N, Yoshida H, Miyazaki Y, et al. Angiotensin II inhibits glucose uptake of skeletal muscle via the adenosine monophosphate-activated protein kinase pathway. J Am Soc Hypertens. 2007;1:251–255
  16. Foianini KR, Steen MS, Kinnick TR, Schmit MB, Youngblood EB, Henriksen EJ. Effects of exercise training and ACE inhibition on insulin action in rat skeletal muscle. J Appl Physiol. 2000;89:687–694
  17. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11–34
  18. Henriksen EJ, Jacob S, Fogt DL, Dietze GJ. Effect of chronic bradykinin administration on insulin action in an animal model of insulin resistance. Am J Physiol. 1998;275:R40–R45

 Conflict of interest: none

PII: S1933-1711(08)00150-2

doi: 10.1016/j.jash.2008.08.002

Journal of the American Society of Hypertension
Volume 3, Issue 1 , Pages 3-8 , January 2009

Article Tools

* Image Usage & Resolution